BRIEF—Daiichi reorganizes R&D structure

Shares of Japanese drugmaker Daiichi Sankyo (TYO: 4568) moved up almost 2% to 4,279 yen today, as it revealed a decision to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare, headquartered in Edogawa-ku, Tokyo.

Daiichi Sankyo will absorb RD Novare's functions into its own organization further to strengthen its R&D capabilities.

RD Novare, which around 400 employees, was founded as Daiichi Sankyo RD Associe Co, in 2006 to support Daiichi Sankyo’s drug discovery and clinical development.

In 2011, the company name was changed to the current one.

RD Novare, which has a cutting-edge research technology infrastructure and a strong clinical development capability, plays a role in the Daiichi Sankyo group of companies’ R&D by contributing to the creation of innovative pharmaceuticals.

RD Novare will conclude its business as a corporate entity on March 31, 2024.

With this reorganization to further enhance the productivity of its R&D, Daiichi Sankyo will merge R&D strengths within the Daiichi Sankyo group of companies, leading to the construction and implementation of a consistent research strategy for drug discovery, rapid decision-making, and the strengthening of global clinical development for the 5DXd-ADCs, including Enhertu (trastuzumab deruxtecan).